New Hepatitis C Treatment Therapies at the Center for Liver Disease and Transplantation

by Columbia Surgery on November 1, 2012

More than 3 million Americans suffer from chronic infection with the hepatitis C virus. Often considered a “silent killer, ” an infected individual may go for years without symptoms before liver damage even becomes apparent. As the disease progresses, it can cause long-term damage to the liver and may lead to liver dysfunction or failure. Cirrhosis, or end-stage liver disease, caused by the chronic hepatitis C infection, is currently the leading indication of the liver transplants in the United States.

Elizabeth Verna, MD, MS

Elizabeth Verna, MD, MS

Recently, the development of new drugs for hepatitis C has changed the management of liver transplant patients. Two newly approved medications are now being combined with traditional treatments to form a powerful new drug cocktail, improving the outcomes among patients with this challenging disease. The new cocktail, part of the arsenal of treatment at the Center for Liver Disease and Transplantation, adds the newly approved drugs (telaprevir and boceprevir) to antivirals already in use for hepatitis C (pegylated interferon and ribavirin). Together, the formula increases the cure rate from 40-50% to 70-80% and shortens the treatment time by half.

Robert S. Brown, Jr., MD, MPH

Robert S. Brown, Jr., MD, MPH

Join us November 14th at 1:00 PM/ET on Columbia Surgery Blog Talk Radio to chat with Hepatologist Elizabeth Verna, MD, MS, Assistant Professor of Medicine at NYP/Columbia’s Center for Liver Disease and Transplantation and Robert S. Brown Jr., MD, MPH, Director of the Center for Liver Disease and Transplantation. Speak to our expert about these new and exciting treatment options and learn more about Hepatitis C and the triple viral therapy medications. Dr. Verna will answer your questions live, such as:

      • Who would be a good candidate for this new treatment?
      • How does the triple viral therapy medications work together to better target the Hepatitis C infection?
      • What is triple viral therapy’s role in liver transplantation?

To submit a question for our doctors before the show, visit our question submission form or tweet an “@” reply to @columbiasurgery.

Then on November 14th at 1:00 PM/ET log into Columbia Surgery Blog Talk Radio Channel to listen to the show. If you’d like to speak to Dr. Verna and Dr. Brown live, call 347-539-5189 while we are on the air.

Listen to internet radio with ColumbiaSurgery on Blog Talk Radio

Related Link:
New Hepatitis C Treatments Blog Talk Radio Program Transcript

{ 2 comments… read them below or add one }

aisha March 13, 2014 at 1:51 pm

my mother is 70 years old. she has been diagnosed by HCV since 2001 and got treatment of interforn during 2004 . but the virus did not responded and her consultant didn’t tried to treat her again. considering the success rate not so much encouraging .now she has been diagnosed with mild ascites as well. kindly guide me whether this new treatment will be helpful for her. waiting for your reply

Columbia Surgery March 13, 2014 at 2:01 pm

Hi Aisha,

Thank you for your question. Unfortunately, this Blog Talk Radio program has already occurred. I would also like to turn your attention to our most recent webinar, which provided updates about new treatment options. You can watch an archived version of the webinar on our YouTube Channel. We hope this helps provide you and your mother with additional information about new treatment options.

For more information about Hepatitis C or to arrange a consultation with Dr. Brown, call the Center for Liver Disease and Transplantation at 877-LIVERMD (877-548-3763) or visit Thank you.

Leave a Comment

Previous post:

Next post: